For over a decade, partnering with the 12^th Clinical Biomarkers & CDx Summit has been a proven way to attract the attention of precision medicine’s top decision makers.

Witnessing a number of exciting Drug-Dx approvals by the FDA in 2021, for precision & targeted therapy developers the race to market is becoming fiercer in 2022.

As the field continues to rapidly evolve, the need to identify & meet cutting edge service providers is business critical.